… we continue to analyze data from the Illuminate trial of sepofarsen and identify next steps for the program, if any,” … as solid – ProQR has deep RNA expertise, a pipeline beyond sepofarsen, an exciting RNA-editing platform, and a strong …
… with Rett Syndrome Research Trust Completed divestment of sepofarsen and ultevursen ophthalmic programs to Laboratoires … completed the divestment of late-stage ophthalmic assets, sepofarsen and ultevursen, to Laboratoires Théa who will …
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) will host a Research & Development Day for investors on Tuesday, January 29 at 8:00 am ET at the Lotte New York Palace Hotel in New York, NY.
QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse eventsQR-421a is the second ophthalmology program where clinical activity was predicted by tra